Citadel Advisors
BTTX

Citadel Advisors’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Citadel Advisors’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,000
Closed -$585 – 15745
2023
Q4 		$585 Sell
3,000
-1,600
-35% -$348 ﹤0.01% 13996
2023
Q3 		$1.77K Buy
+4,600
New +$3.1K ﹤0.01% 13810
2023
Q2 		– Sell
-48,300
Closed -$35.2K – 15510
2023
Q1 		$35.2K Sell
48,300
-114,200
-70% -$134K ﹤0.01% 12579
2022
Q4 		$182K Buy
162,500
+27,300
+20% +$40.3K ﹤0.01% 10298
2022
Q3 		$238K Buy
135,200
+26,300
+24% +$48K ﹤0.01% 10057
2022
Q2 		$170K Buy
108,900
+12,300
+13% +$20.6K ﹤0.01% 10858
2022
Q1 		$191K Sell
96,600
-27,000
-22% -$93.3K ﹤0.01% 11597
2021
Q4 		$575K Buy
+123,600
New +$1.01M ﹤0.01% 9355

Other funds holding BTTX

CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Citadel Advisors's BTTX Position: Q1 2024 in Review

Citadel Advisors sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 216,165 shares — an estimated $42.2K sold.

Citadel Advisors first reported a position in BTTX in Q4 2021 and held it in 4 quarters. The position peaked at $59K in Q4 2021. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

  • Citadel Advisors reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 216,165 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $42.2K.
  • Citadel Advisors first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Citadel Advisors's Better Therapeutics, Inc. Common Stock position peaked at $59K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.